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No presente trabalho descrevemos a síntese e a avaliação da atividade antiproliferativa,
frente a linhagens de células tumorais humanas, de derivados do R-(+)-limoneno (3-18)
contendo uma unidade tiouréia substituída. Os derivados com substituintes arílicos (3-6)
exibiram atividade citostática frente a todas linhagens testadas, com inibição de 50% do
crescimento celular (GI
50
) em concentrações na faixa de 2,5 a 24 μmol L-1. Os compostos
3, 10, 12 e 16 foram os mais ativos, com GI
50 
na faixa de 0,41 a 3,0 μmol L-1, frente a
diferentes linhagens celulares.
A series of R-(+)-limonene derivatives bearing a substituted thiourea moiety (3-13) and
five S-methyl analogs (14-18) were synthesized and evaluated for their in vitro
antiproliferative activity against human cancer cell lines. Compounds bearing aromatic
substituents (3-6) exhibit cytotastic activity in the full panel of cell lines tested, with GI
50
values in the range of 2.5 to 24 μmol L-1. Compounds 3, 10, 12 and 16 were the most active
with GI
50 
values in the range of 0.41 to 3.0 μmol L-1, against different cell lines.
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Introduction
In the last years several approaches have been
employed for cancer therapy, and to discover and develop
novel therapeutic agents for the treatment of malignancy.
In this context, the use of natural products as prototypes
has been pointed out as one of the successful approaches
to discover novel anticancer drugs.
Monoterpenes are a class of compounds, which
occurs naturally in plant, and possess a range of pharma-
cological properties. Several studies have demonstrated
the efficacy of this class of compounds as potential
anticancer agents.1-3 D-Limonene, a monoterpene found
in a variety of foods and essential oils, have been shown
to exert chemopreventive and chemotherapeutic
activities in a variety of carcinogen-induced animal
tumor models.4-7 Dietary administration of D-limonene
causes complete regression of N-nitrosourea (NMU)-
induced and 7,12-dimethylbenzyl[a]anthracene
(DMBA)-induced mammary carcinomas with minimal
toxicity.8,9
As a result of its chemopreventive and chemo-
therapeutic potential, limonene is under clinical trials.
Phase I and pharmacokinetic study in patients with
advanced cancer confirm its low toxicity and support
D-limonene as prototype of a novel class of chemo-
therapeutic drugs.10
The potential use of limonene as an anticancer agent
led us to focus our attention on the synthesis and
antiproliferative activity evaluation of new limonene
derivatives, as part of our research program in this area.
We present herein the synthesis and the results of the
antiproliferative activity evaluation of a series of limonene
derivatives (3-13) bearing a substituted thiourea moiety,
and of five their S-methyl analogues (14-18).
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Results and Discussion
Synthesis
The synthetic route for the preparation of limonene
derivatives is presented in Scheme 1. The limonene
isothiocyanate (2) was obtained from the reaction of
the limonene (1) with HSCN, in chloroform, according
to a previously reported procedure.11,12 Treatment of 2
with different amines (primary, heterocyclic and
aromatic) afforded compounds 3-13. For primary and
heterocyclic amines the reactions were carried out at
25 oC for 15 h, by using 2 equivalents of the amine in
chloroform as solvent, and the title thioureas were
obtained in 67 – 97% yield. However, limited yields
(20-30%) were observed for the reaction of 2 with
aromatic amines such as aniline, o-toluidine, o-
anisidine and p-bromoaniline. In these cases, reactions
were performed with a large excess of amine, at 100 oC
for 24 h. The products (3-13) were characterized by
analysis of their spectroscopic data. The presence of
the C=S group was evidenced by the IR absorption
bands at 1523-1566 and 1250-1410 cm-1, together with
the signal at δ 177.3 – 181.8 in the 13C NMR spectra.





 5.30-5.40 (1H, brs, H-2)/119.7-120.5
(C-2), 1.30-1.49 (3H, s, H-8)/24.1-24.9 (C-8), 1.34-1.50
(3H, s, H-9)/24.2-25.4 (C-9) and 1.61-1.73 (3H, s, H-
10)/23.0-23.5 (C-10) in the 1H/13C NMR spectra. The
NMR data were also consistent for the substituents
attached to the nitrogen atom N-1, as showed in the
Experimental Section. The EI-mass spectra showed
peaks at m/z 58 and at m/z (M+• - 135) as main fragments.
The proposed mechanisms for the fragmentation are
shown in Figure 1.
The S-methylated derivatives (14-18) were prepared
from the reaction of the corresponding thioureas with
methyl iodide at 0 oC, in chloroform, for 24 h in
quantitative yields. The 1H NMR spectra of the S-
methylthioureas showed signal at δ 2.78 – 2.85
corresponding to the SCH
3
 group. The formation of S-
methythiourea was also evidenced by the presence of the
signals at δ 16.9 – 18.5 (S-CH
3
) and δ 143.7 – 169.2 (C=N)
in the 13C NMR spectra, besides of the absorption at 1600-
1690 cm-1 (C=N), in the IR spectra.
Antiproliferative activity
The results of the antiproliferative assays are showed
in Tables 1 and 2. The response parameter GI
50
 (Table 1)
refers to the drug concentration that produce a 50%
reduction of cellular growth when compared to untreated
control cells. Table 2 includes data for the compounds that
reached TGI and LC
50
 values. The TGI and LC
50
 parameters
refer, respectively, to the drug concentration for total growth
inhibition, and that for killing 50% of the cells.
As shown in Table 1, the compounds bearing aromatic
substituents (3-6) exhibit cytotastic activity against all
cancer cell lines tested, with GI
50
 values in the range of
2.5 to 24 μmol L-1. Analysis of TGI and LC
50
 data
presented in Table 2 show that compounds 3-5 had higher
potency for total growth inhibition, and for killing 50%
of the cells. From this series, compound 3 was the most
active, with GI
50
 and TGI values of 2.5 μmol L-1 and
22.5 μmol L-1, respectively, against breast resistant NCI/
ADR cancer cell line. On the other hand, compounds 7-
18 of the aliphatic series exhibit different profiles and
dependence on the nature of the substituent on the
nitrogen atom. Compared to aromatic series, the
specificity was increased with the most of the compounds
Figure 1. Proposed mechanism for formation of the fragments a) m/z 58
and b) m/z (M+· - 135).Scheme 1.
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of the aliphatic series exhibiting smaller GI
50
 values for
leukemic K-562 cell line. From the thiourea aliphatic
series, compounds 9 and 12 showed potent activity and
particular selectivity against leukemic K-562 cell line
with GI
50 
values of 6.6 and 3.0 μmol L-1, respectively.
The replacement of the 1-N-methyl group of the
compound 12 for an oxygen results in the inactive
compound 13. The thiourea 10 exhibits potent
antiproliferative activity against ovarian OVCAR and
breast resistant NCI/ADR with GI
50 
3.0 and 6.1 μmol
L-1, respectively. S-methylation of thioureas bearing
aliphatic substituents results in changes in the
antiproliferative activity profiles. Conversion of the
thiourea 10 to the S-methylthiourea analogue 16, led to





L-1 and high selectivity against leukemia K-562 cell lines.
Conclusions
In this paper we report the synthesis and cytotoxic
evaluation of a series of new limonene derivatives
containing a substituted thiourea moiety. The results show
the potentiality of some compounds, particularly 3, 10,
12 and 16, as inhibitors of tumor cells proliferation. Some
compounds bearing aromatic substituents were also able
to kill 50% of the breast resistant NIC/ADR (compounds
Table 1. GI
50
 values (in μmol L-1 concentrations) of the limonene derivatives (3-18)
Cancer cell lines
Compounds R1 R2
Melanoma Breast Lung Leukemia Ovarian Prostate Colon Renal Breast resistant
UACC-62 MCF7 NCI-460 K-562 OVCAR PCO-3 HT29 786-0 NCI/ADR
Thioureas Aromatic
3 Ph H 13.9 18.4 17.3 nt 16.6 15.6 24.0 23.2 2.5
4 2-Me-Ph H 12.0 21.0 18.3 18.7 17.2 19.8 9.3 16.1 12.4
5 2-OMe-Ph H 11.8 13.6 15.0 10.5 9.5 11.0 18.2 12.7 8.0
6 4-Br-Ph H nt 21.5 19.9 20.1 16.7 16.5 14.6 20.9 19.0
Aliphatic
7 n-Butyl H >100 >100 >100 39.5 98.1 >100 60.6 92.4 54.1
8 i-Propyl H 31.8 70.7 29.5 18.9 28.3 >100 30.7 32.6 13.8
9 i-Pentyl H 97.7 46.5 54.3 6.6 56.2 62.6 17.5 92.1 32.7
10 Cyclohexyl H nt 37.3 33.9 16.3 3.0 12.5 nt 26.5 6.1
11 Pyrrolidyl 53.3 26.1 34.5 23.6 44.3 43.0 36.8 59.6 28.5
12 1-N-Methylpiperazyl >100 >100 >100 3.0 >100 >100 >100 >100 88.0
13 Morpholyl >100 >100 >100 >100 >100 >100 >100 >100 >100
S-Methylthioureas
14 i-Propyl 83.8 >100 >100 25.4 >100 >100 81.8 >100 85.3
15 i-Pentyl 28.9 16.0 17.6 88.7 91.3 16.2 16.7 14.8 10.3
16 Cyclohexyl 60.7 60.7 58.9 0.41 39.1 62.5 16.7 75.6 75.6
17 Pyrrolidyl 90.0 >100 >100 >100 60.9 >100 >100 >100 91.3
18 1-N-Methylpiperazyl >100 >100 >100 76.7 >100 >100 >100 >100 >100
Doxorubicin 2.36 8.84 1.21 3.04 9.67 7.88 2.73 1.76 >100
nt = not tested.
Table 2. TGI values and LC
50 
(values in parenthesis), in μmol L-1 concentrations
Cancer cell lines
Compounds R1 R2
Melanoma Breast Lung Leukemia Ovarian Prostate Colon Renal Breast resistant
UACC-62 MCF7 NCI-460 K-562 OVCAR PCO-3 HT29 786-0 NCI/ADR
Thioureas
3 Ph H 34.6 55.5 86.6 >100 >100 58.9 >100 86.6 22.5 (76.6)
4 2-Me-Ph H 29.7 (80.9) 86.9 47.2 >100 49.5 >100 >100 29.8 (65.0) 30.0 (65.0)
5 2-OMe-Ph H 39.2 64.6 39.5 >100 32.0 58.0 >100 26.8 (57.7) 26.9
6 4-Br-Ph H >100 >100 71.0 >100 72.0 >100 95.0 71.0 71.0
9 i-Pentyl H >100 >100 >100 95.0 >100 >100 >100 >100 >100
S-Methylthioureas
15 i-Pentyl >100 68.3 87.8 >100 >100 >100 87.8 58.0 70.6
16 Cyclohexyl >100 >100 >100 82.5 >100 >100 93.0 >100 >100
Doxorubicin 64.0 6.86 >100 >100 92.1 >100
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3 and 4), melanoma UACC-62 (compound 4), and renal
786-0 (compounds 4 and 5) cancer cell lines.
Experimental
IR spectra were recorded on KBr pellets in a Bomem
model MB-100 spectrophotometer. Mass spectra were
measured on Shimadzu GC/MS, QP 2000A, at 70 eV. 1H
and 13C NMR spectra were recorded on a Varian Mercury
Plus 300 MHz in CDCl
3
 and TMS as internal reference.
Column chromatography was performed on silica gel
Merck 230-400 mesh ASTM.
General procedure for thioureas 3 – 13
To a solution of limonene isothiocyanate 2 (1 mmol)
in CHCl
3
 (10 mL) was added drop-wise the amine (2
mmol).11,12 The solution was kept at room temperature for
15 hours and then the solvent was removed under reduced
pressure. For aromatic amines, reactions were performed
with a large excess of amine, without solvent, at 100 oC
for 24 h. The residue was purified by column chromato-
graphy using hexane and a mixture of hexane-ethyl acetate
in increasing polarity as solvent.
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(phenyl)]thiourea (3). Yield: 30%; IR ν
max
/cm-1: 3387 (N-
H), 3156 (C-H arom), 1590 (C=C arom), 1540 and 1298







]+); 1H NMR (300 MHz, CDCl
3
):
δ 1.18 and 1.62 (1H each, m, H-5), 1.40 (3H, s, H-8),
1.45 (3H, s, H-9), 1.61 (3H, s, H-10), 1.84 and 1.90 (4H,
m, H-3 and H-6), 2.59 (1H, m, H-4), 5.36 (1H, brs, H-
2), 7.20 (2H, d, J 7.5 Hz, H-2’ and H-6’), 7.29 (1H, t, J
7.5 Hz, H-4’), 7.43 (2H, t, J 7.5 Hz, H-3’ and H-5’); 13C
NMR (75.5 MHz, CDCl
3
): δ 23.5 (C-10), 24.2 (C-9),
24.3 (C-5), 24.5 (C-8), 26.7 (C-3), 31.2 (C-6), 41.1 (C-
4), 59.5 (C-7), 120.5 (C-2), 125.2 (C-2’ and C-6’), 127.1
(C-4’), 130.2 (C-3’ and C-5’), 134.3 (C-1), 136.8 (C-
1’), 179.5 (C=S).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-(2-
methylphenyl)]thiourea (4). Yield: 30%. IR ν
max
/cm-1: 3367
(N-H), 3173 (C-H arom), 1643 (C=C arom), 1621 (C=C),
1533 and 1251 (C=S); EI-MS m/z (rel. int.): 302 (M+•,
10), 167 (100, M+• - 135, [H
2
NCSNH-2-methylphenyl]+),
91 (45), 58 (70), 41 (46); 1H NMR (300 MHz, CDCl
3
): δ
1.39 (3H, s, H-8), 1.45 (3H, s, H-9), 1.61 (3H, s, H-10),
1.75 (2H, m, H-5), 1.93 (4H, m, H-3 and H-6), 2.29 (3H,
s, CH
3
-Ar), 2.48 (1H, m, H-4), 5.30 (1H, brs, H-2), 7.20
(1H, m, H-6’), 7.25 (1H, m, H-5’), 7.28 (1H, m, H-4’),





-Ar), 23.5 (C-10), 24.1 (C-8), 24.2 (C-5), 24.4 (C-
9), 26.6 (C-3), 31.2 (C-6), 41.4 (C-4), 59.2 (C-7), 120.5
(C-2), 127.7 (C-6’), 127.8 (C-5’), 127.9 (C-2’), 128.7 (C-
4’), 131.9 (C-3’), 134.3 (C-1), 136.0 (C-1’), 179.9 (C=S).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(2-methoxyphenyl)]thiourea (5). Yield: 31%; IR ν
max
/cm-1:
3370 (N-H), 3048 (C-H arom), 1599 and 1535 (C=C), 1460
and 1250 (C=S); EI-MS m/z (rel. int.): 318 (M+•, 7), 183





N-2-methoxyphenyl]+·), 93 (27), 58 (100), 41 (43); 1H
NMR (300 MHz, CDCl
3
): δ 1.42 (3H, s, H-8), 1.48 (3H, s,
H-9), 1.63 (3H, s, H-10), 1.77 (2H, m, H-5), 1.90 (4H, m,
H-3 and H-6), 2.00 (1H, m, H-4), 3.84 (3H, s, OCH
3
), 5.36
(1H, brs, H-2), 6.92 (1H, m, H-3’), 6.94 (1H, d, J 7.8 Hz,
H-6’), 6.98 (1H, t, J 7.8 Hz, H-5’), 7.20 (1H, t, J 7.8 Hz,
H4’); 13C NMR (75.5 MHz, CDCl
3
): δ 23.4 (C-10), 24.3
(C-5), 24.6 (C-8), 24.6 (C-9), 26.7 (C-3), 31.2 (C-6), 41.7
(C-4), 55.8 (OCH
3
), 59.3 (C-7), 110.3 (C-4’),120.5 (C-2),
121.0 (C- 5’ and C-6’), 124.5 (C-3’), 134.1 (C-1’), 134.2
(C-1), 154.6 (C-2’), 179.3 (C=S).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-(4-
bromophenyl)]thiourea (6). Yield: 20%; IR ν
max
/cm-1: 3281
(N-H), 3103 (C-H), 1578 and 1530 (C=C, arom.), 1488
and 1364 (C=S); EI-MS m/z (rel. int.): 366 (M+•, 7), 215
(23), 58 (100); 1H NMR (300 MHz, CDCl
3
): δ 1.24 and
1.68 (1H each, m, H-5’), 1.42 (3H, s, H-8), 1.48 (3H, s,
H-9), 1.63 (3H, s, H-10), 1.68 and 1.97 (1H each, m, H-
3), 1.96 (2H, m, H-6), 2.59 (1H, m, H-4), 5.36 (1H, brs,
H-2), 7.09 (2H, d, J 8.7 Hz, H-2’ and H-6’), 7.54 (2H, d,
J 8.7 Hz, H-3’ and H-5’); 13C NMR (75.5 MHz, CDCl
3
):
δ 23.5 (C-10), 24.4 (C-5), 24.6 (C-8), 24.6 (C-9), 26.7
(C-3), 31.2 (C-6), 40.9 (C-4), 59.7 (C-7), 120.4 (C-2),
120.6 (C-4’), 126.8 (C2’ and C-6’), 133.4 (C3’ and C-5’),
134.4 (C-1), 136.0 (C-1’), 179.4 (C=S).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(butyl)]thiourea (7). Yield: 97%; IR ν
max
/cm-1: 3269 (N-
H), 1543 and 1342 (C=S); EI-MS m/z (rel. int.): 268 (M+•,
10), 133 (100, M+• - 135, [H
2
NCSNH-butyl]+), 58 (68), 41
(60); 1H NMR (300 MHz, CDCl
3
): δ 0.95 (3H, t, J 7.2 Hz,
H-4’); 1.35 (3H, s, H-8), 1.39 (3H, s, H-9), 1.41 (2H, m,
H-3’), 1.60 (2H, m, H-6), 1.64 (3H, s, H-10), 1.82 (2H,
m, H-5), 1,99 (3H, m, H-3 and H-4), 2.01 (2H, m, H-2’),
3.54 (2H, q, J 6.0 Hz, H-1’), 5.40 (1H, brs, H-2); 13C
NMR (75.5 MHz, CDCl
3
): δ 13.7 (C-4’), 20.1 (C-3’), 23.2
(C-10), 24.2 (C-5), 24.8 (C-8), 25.0 (C-9), 26.5 (C-3),
30.9 (C-2’), 31.2 (C-6), 58.3 (C-7), 42.2 (C-4), 45.1 (C-
1’), 120.0 (C-2), 133.9 (C-1), 180.8 (C=S).
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N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(isopropyl)]thiourea (8). Yield: 84%; IR ν
max
/cm-1: 3272
(N-H), 1538 and 1325 (C=S); EI-MS m/z (rel. int.): 254
(M+•, 7), 119 (100, M+• - 135, [H
2
NCSNH-isopropyl]+),
58 (65), 41 (60); 1H NMR (300 MHz, CDCl
3
): δ 1.23




), 1.35 (3H, s, H-8), 1.40
(3H, s, H-9), 1.65 (3H, s, H-10), 1.78 (2H, m, H-5), 1.99
(5H, m, H-3, H-4 and H-6), 4.40 (1H, m, H-1’), 5.40 (1H,







), 23.2 (C-10), 24.2 (C-5), 24.9 (C-8), 25.2
(C-9), 26.6 (C-3), 30.9 (C-6), 42.5 (C-4), 47.2 (C-1’), 58.3
(C-7), 120.0 (C-2), 134.0 (C-1), 179.8 (C=S).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(isopentyl)]thiourea (9). Yield: 80%; IR ν
max
/cm-1: 3258
(N-H), 1643 (C=C), 1537 and 1322 (C=S); (KBr); EI-MS
m/z (rel. int.): 282 (M+·•, 10), 147 (100, M+• - 135,
[H
2
NCSNH-isopentyl]+), 58 (70); 41 (65); 1H NMR (300
MHz, CDCl
3







1.30 and 1.83 (1H each, m, H-5), 1.34 (3H, s, H-8), 1.38







m, H-3), 1.65 (3H, s, H-10), 1.99 (3H, m, H-4 and H-6),
4.23 (1H, m, H-1’), 5.36 (1H, brs, H-2); 13C NMR (75.5
MHz, CDCl
3














), 31.0 (C-6), 42.8 (C-4), 58.2 (C-7),
58.3 (C-1’), 119.7 (C-2), 134.1 (C-1),180.7 (C=S).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(cyclohexyl)]thiourea (10). Yield: 80%; IR ν
max
/cm-1: 3258
(N-H); 1540 and 1338 (C=S); EI-MS m/z (rel. int.): 294
(M+•, 10), 58 (100), 41 (60); 1H NMR (300 MHz, CDCl
3
):
δ 1.37 (3H, s, H-9), 1.34 (3H, s, H-8), 1.60 (m, H-4’),
1.65 (3H, s, H-10), 1.67 (4H, m, H-3’and H-5’),1.80 (2H,
m, H-6), 1.81 (4H, m, H-3 and H-5), 1,93 (1H, m, H-4),
2.02 (4H, m, H-2’and H-6’), 4.12 (1H, m, H-1’), 5.36
(1H, brs, H-2); 13C NMR (75.5 MHz, CDCl
3
): δ 23.3 (C-
10), 24.2 (C-5), 24.7 (C-3’and C-5’), 24.9 (C-8), 25.2 (C-
9), 25.4 (C-4’), 26.6 (C-3), 31.0 (C-6), 32.9 (C-2’and C-
6’), 42.7 (C-4), 53.9 (C-1’), 58.3 (C-7), 120.0 (C-2), 134.0
(C-1), 179.7 (C=S).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(pyrrolidyl)]thiourea (11). Yield: 67%; IR ν
max
/cm-1: 3395
(N-H), 1643 (C=C), 1531 and 1347 (C=S); EI-MS m/z
(rel. int.): 266 (M+•); 233 (28); 131 (100, M+• - 135;
[H
2
NCSNH-pyrrolidyl]+), 114 (92); 93 (30); 58 (38); 41
(58); 1H NMR (300 MHz, CDCl
3
): δ 1.25 and 1.78 (1H
each, m, H-5), 1.49 (3H, s, H-8), 1.55 (3H, s, H-9), 1.64
(3H, s, H-10), 1.77 and 2.04 (1H each, m, H-3), 1.98
(2H, m, H-6), 1.98 (4H, m, H-2’and H-3’), 2.70 (1H,
tdd, J 12.0, 2.4 and 2.1, H-4), 3.55 (4H, m, H-1’ and H-
4’), 5.37 (1H, brs, H-2); 13C NMR (75.5 MHz, CDCl
3
):
δ 23.3 (C-10), 24.1 (C-5), 24.6 (C-8), 24.9 (C-9), 25.5
(C-2’and C-3’), 26.6 (C-3), 31.1 (C-6), 40.8 (C-4), 49.2
(4H, m, C-1’ and C-4’), 58.9 (C-7), 120.6 (C-2), 134.0
(C-1), 177.3 (C=S).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-(N-
methylpiperazyl)]thiourea (12). Yield: 90%; IR ν
max
/cm-1:
3438 (N-H), 1629 (C=C), 1566 and 1410 (C=S); EI-MS
m/z (rel. int.): 295 (M+•); 195 (20), 121 (34), 93 (64), 58
(100), 41 (97); 1H NMR (300 MHz, CDCl
3
): δ 1.46 (3H,
s, H-8), 1.53 (3H, s, H-9), 1.63 (3H, s, H-10), 1.73 (2H,
m, H-5), 1.81 and 1.96 (1H each, m, H-3), 1.96 (2H , m,
H-6), 2.30 (3H, s, NCH
3
), 2.43 (4H, t, J 5.1 Hz, H-2’and
H-3’), 2.81 (1H, m, H-4), 3.78 (4H, t, J 5.1 Hz, H-1’and
H-4’), 5.36 (1H, brs, H-2); 13C NMR (75.5 MHz, CDCl
3
):
δ 23.0 (C-10), 23.8 (C-5), 24.2 (C-9), 24.3 (C-8), 26.2
(C-3), 30.7 (C-6), 39.9 (C-4), 45.4 (NCH
3
), 46.8 (C-1’
and C-4’), 54.2 (C-2’ and C-3’), 58.9 (C-7), 120.3 (C-2),
133.5 (C-1), 180.8 (C=S).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(morpholyl)]thiourea (13). Yield: 88%; IR ν
max
/cm-1: 3408
(N-H), 1523 and 1347 (C=S); 1H NMR (300 MHz, CDCl
3
):
δ 1.48 (3H, s, H-8), 1.54 (3H, s, H-9), 1.65 (2H, m, H-5),
1.73 (3H, s, H-10), 2.02 (4H, m, H-3 and H-6), 2.75 (1H,
m, H-4), 3.73 (8H, m, H-1’, H-2’, H-3’and H-4’), 5.36
(1H, brs, H-2); 13C NMR (75.5 MHz, CDCl
3
): δ 23.3 (C-
10), 24.3 (C-5), 24.6 (C-8), 24.7 (C-9), 26.5 (C-3), 30.7
(C-6), 44.5 (C-4), 47.4 (C-1’and C-4’), 59.5 (C-7), 66.3
(C-2’and C-3’), 119.7 (C-2), 134.1 (C-1), 181.8 (C=S).
General procedure for S-methylthioureas 14-18
To a solution of thiourea (1 mmol) in CHCl
3
 (10 mL)
was added methyl iodide (5 mmol) at 0 oC. The mixture
was kept at 0 oC for 24 h and then the solvent and excess
of methyl iodide were removed under reduced pressure
to give the salt of the corresponding S-methylthiourea in
quantitative yield for all compounds.
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(isopropyl)]-S-methylthiourea (14). IR ν
max
/cm-1: 3193 (N-
H), 1600 (C=N); EI-MS m/z (rel. int.): 268 (7, M+•), 220
(68, M+• – CH
3
SH), 205 (57), 128 (100), 127 (60), 93
(77), 58 (91), 43 (96), 41 (85); 1H NMR (300 MHz,
CDCl
3





s, H-8), 1.58 (3H, s, H-9), 1.65 (3H, s, H-10), 1.76 (2H,
m, H-5), 1.93 (4H, m, H-3 and H-6), 2.27 (1H, m, H-4),
2.85 (3H, s, SCH
3
), 4.30 (1H, m, H-1’), 5.35 (1H, brs, H-
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2); 13C NMR (75.5 MHz, CDCl
3







), 23.3 (C-10), 24.4 (C-5), 25.1 (C-8), 25.7
(C-9), 26.7 (C-3), 30.8 (C-6), 42.7 (C-4), 51.2 (C-1’), 57.4
(C-7), 120.1 (C-2), 134.1 (C-1), 143.7 (C=N).
N-[1-(4R)-(4-isoproyl-1-methylcyclohexenyl)]-N’-[2-
(isopentyl)]-S-methylthiourea (15). IR ν
max
/cm-1: 3347 (N-
H), 1690 (C=N); EI-MS m/z (rel. int.): 248 (40, M+•
– CH
3
SH), 233 (50), 219 (55), 128 (81), 127 (49), 93 (61),
58 (74); 43 (100), 41 (86); 1H NMR (300 MHz, CDCl
3
):






), 1.33 (1H, m, H-
5), 1.55 (3H, s, H-8), 1.58 (3H, s, H-9), 1.65 (3H, s, H-







1.94 (2H, m, H-3), 2.01 (2H, m, H-6), 2.26 (1H, m, H-4),
2.78 (3H, s, SCH
3
), 3.78 (1H, m, H-1’), 5.37 (1H, brs, H-
2); 13C NMR (75.5 MHz, CDCl
3









), 23.3 (C-10), 24.4 (C-5), 25.1 (C-8), 25.6






), 30.8 (C-6), 42.8
(C-4), 61.5 (C-7), 63.4 (C-1’), 119.4 (C-2),134.4 (C-1),
169.2 (C=N).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(cyclohexyl)]-S-methyl-thiourea (16). IR ν
max
/cm-1: 3186
(N-H), 1685 (C=N), 1591 (C=C); EI-MS m/z (rel. int.):
308 (M+•), 261 (31, M+• – CH
3
S·), 128 (63), 127 (39), 93
(53), 58 (55), 55 (54), 43 (57), 41 (100); 1H NMR (300
MHz, CDCl
3
): δ 1.34 and 1.81 (1H each, m, H-6), 1.55
(3H, s, H-8), 1.57 (3H, s, H-9), 1.62 (2H, m, H-4’), 1.65
(3H, s, H-10), 1.81 (2H, m, H-5), 1.81 (4H, m, H-3’and
H-5’), 1.93 (4H, m, H-2’and H-6'), 1.93 (2H, m, H-3),
2.25 (1H, m, H-4), 2.83 (3H, s, SCH
3
), 3.88 (1H, m, H-





), 23.3 (C-10), 24.4 (C-4’), 24.6 (C-5), 24.8
(C-3’ and C-5’), 25.6 (C-8 and C-9), 26.7 (C-3), 30.7
(C-6), 32.6 (C-2’and C-6’),
 
42.7 (C-4), 56.8 (C-1’), 63.4
(C-7), 119.4 (C-2), 134.3 (C-1), 168.1 (C=N).
N-[1-(4R)-(4-isopropyl-1-methylcyclohexenyl)]-N’-[2-
(pyrrolidyl)]-S-methyl-thiourea (17). IR ν
max
/cm-1: 1677
(C=N), 1584 (C=C); EI-MS m/z (rel. int.): 280 (M+•),142
(52), 128 (93), 127 (69), 84 (44), 70 (42), 57 (42), 43
(100), 42 (87), 41 (40); 1H NMR (300 MHz, CDCl
3
):
δ 1.36 and 1.82 (1H each, m, H-5), 1.60 (3H, , H-9), 1.62
(3H, s, H-8), 1.65 (3H, s, H-10), 1.82 (m, H-5), 1.96 (2H,
m, H-3), 2.01 (2H, m, H-6), 2.18 (4H, m, H-2’and H-3’),
2.35 (1H, m, H-4), 2.70 (3H, s, SCH
3
), 4.04 (4H, m, H-
1’and H-4’), 5.37 (1H, brs, H-2); 13C NMR (75.5 MHz,
CDCl
3
): δ 17.6 (SCH
3
), 23.5 (C-10), 24.6 (C-5), 25.4 (C-
2’and C-3’), 26.2 (C-8), 26.6 (C-9), 27.1 (C-3), 31.1 (C-
6), 43.3 (C-4), 53.5 (C-1’and C-4’), 64.1 (C-7),119.9 (C-
2), 134.4 (C-1), 164.2 (C=N).
N-[1-(4R)-(4-isoproyl-1-methylcyclohexenyl)]-N’-[2-(N-
methypiperazyl)]-S-methyl-thiourea (18). IR ν
max
/cm-1:
1675 (C=N), 1610 (C=C); EI-MS m/z (rel. int.): 304 (M+•),
195 (43), 136 (55), 121 (28), 93 (100), 81 (53), 58(16), 44
(56), 41 (75); 1H NMR (300 MHz, CDCl
3
): δ 1.27 (3H, s,
H-8), 1.28 (3H, s, H-9), 1.65 (3H, s, H-10), 1.76 (2H, m,
H-5), 1.80 and 1.97 (1H each, m, H-3), 1.97 (3H, m, H-4
and H-6), 2.34 (3H, s, NCH
3
), 2.73 (3H, s, SCH
3
), 3.59
(4H, m, H-1’and H-4’), 3.70 (4H, m, H-2’and H-3’), 5.37





), 23.4 (C-10), 24.3 (C-5), 24.6 (C-8), 24.8 (C-9),
26.9 (C-3), 31.3 (C-6), 42.9 (C-1’and C-4’), 46.2 (C-4),
58.8 (C-7), 61.5 (C-2’and C-3’), 52.2 (NCH
3
), 121.1 (C-
2), 133.9 (C-1), 151.1 (C=N).
Antiproliferative assays
Synthesized compounds were evaluated in vitro
against a nine-cell panel lines consisting of melanoma
UACC-62, breast MCF7, lung NCI-460, leukemia K-
562, ovarian OVCAR, prostate PCO-3, colon HT29,
renal 786-0 and breast resistant NCI/ADR according
NCI standard protocol.17 Doxorubicin was used as
positive control. Assays were performed in a 96-well
plate using four concentrations at 10-fold dilutions
(0.25 mg mL-1 to 250 mg mL-1) for each test compound.
The anticancer activity was deduced from dose-
response curves and three dose response parameters
(GI
50
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